AbbVie (ABBV)
(Delayed Data from NYSE)
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
Pre-Market: $199.87 -0.60 (-0.30%) 8:02 AM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
Pre-Market: $199.87 -0.60 (-0.30%) 8:02 AM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $78.60, marking a -0.11% move from the previous day.
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
by Zacks Equity Research
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
by Zacks Equity Research
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Top Ranked Income Stocks to Buy for June 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 17th.
3 Big Pharma Stocks to Buy Right Now
by Zachary Stutler
These big pharma stocks all have a Zacks Rank #2 or better.
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
by Zacks Equity Research
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $76.95 in the latest trading session, marking a -0.62% move from the prior day.
Top Ranked Growth Stocks to Buy for June 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 10th
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
by Zacks Equity Research
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
by Zacks Equity Research
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
Bet on 5 Top Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Top Ranked Income Stocks to Buy for June 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 6th.
Pfizer to Launch Several Drugs Despite Generic Headwinds
by Zacks Equity Research
Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication
by Zacks Equity Research
Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $75.84 in the latest trading session, marking a -1.13% move from the prior day.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Vertex Selects Triple Combo Regimen for Regulatory Submission
by Zacks Equity Research
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
J&J Stock Up This Year So Far: Will the Momentum Continue?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Glaxo's Shingles Vaccine Shingrix Gets Approval in China
by Zacks Equity Research
GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.
Why Is AbbVie (ABBV) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
J&J's Invokana sNDA Gets Priority Review Status From FDA
by Zacks Equity Research
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes